If you liked this article you might like

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Celgene Beats Estimates, Raises Earnings Outlook

Celgene Beats Estimates, Raises Earnings Outlook

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Pre-Market Activity Shows Gains For Celgene (CELG)

Pre-Market Activity Shows Gains For Celgene (CELG)